Celldex Therapeutics, Inc.
CLDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 5% | -40.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 30.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -8,627.9% | -8,902.4% | -4,698.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -7,753.4% | -7,740.4% | -4,007.8% |
| EPS Diluted | -1.01 | -0.85 | -0.81 | -0.71 |
| % Growth | -18.8% | -4.9% | -14.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |